CY1110424T1 - Πρωτεϊνες ουροκορτινης και χρησεις αυτων - Google Patents

Πρωτεϊνες ουροκορτινης και χρησεις αυτων

Info

Publication number
CY1110424T1
CY1110424T1 CY20081101461T CY081101461T CY1110424T1 CY 1110424 T1 CY1110424 T1 CY 1110424T1 CY 20081101461 T CY20081101461 T CY 20081101461T CY 081101461 T CY081101461 T CY 081101461T CY 1110424 T1 CY1110424 T1 CY 1110424T1
Authority
CY
Cyprus
Prior art keywords
crf
ucn
urp
human
urocortin
Prior art date
Application number
CY20081101461T
Other languages
Greek (el)
English (en)
Inventor
Wylie W Vale
Paul F Sawchenko
Kathy A Lewis
Joan M Vaughan
Teresa M Reyes
Jean E Rivier
John B Hogenesch
Marilyn H Perrin
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation filed Critical Research Development Foundation
Publication of CY1110424T1 publication Critical patent/CY1110424T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57509Corticotropin releasing factor [CRF] (Urotensin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
CY20081101461T 2000-08-04 2008-12-17 Πρωτεϊνες ουροκορτινης και χρησεις αυτων CY1110424T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22325500P 2000-08-04 2000-08-04
US27396901P 2001-03-07 2001-03-07
EP01963759A EP1305334B1 (en) 2000-08-04 2001-07-31 Urocortin proteins and uses thereof

Publications (1)

Publication Number Publication Date
CY1110424T1 true CY1110424T1 (el) 2015-04-29

Family

ID=26917597

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101461T CY1110424T1 (el) 2000-08-04 2008-12-17 Πρωτεϊνες ουροκορτινης και χρησεις αυτων

Country Status (16)

Country Link
US (4) US6838274B2 (https=)
EP (1) EP1305334B1 (https=)
JP (1) JP4873825B2 (https=)
KR (1) KR100879232B1 (https=)
CN (1) CN1484650B (https=)
AT (1) ATE408622T1 (https=)
AU (2) AU2001284683B2 (https=)
CA (1) CA2418144C (https=)
CY (1) CY1110424T1 (https=)
DE (1) DE60135850D1 (https=)
DK (1) DK1305334T3 (https=)
ES (1) ES2313978T3 (https=)
IL (2) IL154102A0 (https=)
PT (1) PT1305334E (https=)
RU (1) RU2278871C2 (https=)
WO (1) WO2002012307A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1305334T3 (da) * 2000-08-04 2009-02-02 Res Dev Foundation Urocortinproteiner og anvendelser deraf
US20020082409A1 (en) * 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
US6812210B2 (en) 2001-03-15 2004-11-02 Research Development Foundation Urocortin-III and uses thereof
US7192924B2 (en) 2002-01-16 2007-03-20 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
US7982018B2 (en) * 2006-10-16 2011-07-19 Conjuchem, Llc Modified corticotropin releasing factor peptides and uses thereof
WO2008157302A2 (en) 2007-06-13 2008-12-24 Research Development Foundation Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling
AU2008297411A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US20100204113A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of stresscopin-related peptide as a therapeutic agent
WO2011025905A1 (en) * 2009-08-28 2011-03-03 Research Development Foundation Urocortin 2 analogs and uses thereof
WO2013063046A1 (en) 2011-10-24 2013-05-02 Research Development Foundation Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors
CN108310396B (zh) 2012-02-14 2022-07-15 加利福尼亚大学董事会 用于心血管疾病和其它病况的旁分泌基因的全身性递送和受调节的表达
JOP20170153A1 (ar) * 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
US12472158B2 (en) 2019-02-27 2025-11-18 Vanderbilt University Methods of treating trigeminal nerve pain
CN110826145B (zh) * 2019-09-09 2020-08-28 西安工业大学 基于超启发式马氏链进化的汽车多参数运行工况设计方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0845035A2 (en) 1995-06-13 1998-06-03 The Salk Institute For Biological Studies Urocortin peptides
DK1305334T3 (da) * 2000-08-04 2009-02-02 Res Dev Foundation Urocortinproteiner og anvendelser deraf
US20020082409A1 (en) 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors

Also Published As

Publication number Publication date
IL154102A0 (en) 2003-07-31
IL154102A (en) 2010-12-30
EP1305334B1 (en) 2008-09-17
RU2003105897A (ru) 2005-01-20
ES2313978T3 (es) 2009-03-16
US20100168021A1 (en) 2010-07-01
US20020127221A1 (en) 2002-09-12
WO2002012307A1 (en) 2002-02-14
CN1484650B (zh) 2012-12-12
ATE408622T1 (de) 2008-10-15
DE60135850D1 (de) 2008-10-30
US6838274B2 (en) 2005-01-04
US7223846B2 (en) 2007-05-29
DK1305334T3 (da) 2009-02-02
AU2001284683B2 (en) 2006-04-27
US8044025B2 (en) 2011-10-25
EP1305334A4 (en) 2005-03-23
RU2278871C2 (ru) 2006-06-27
AU8468301A (en) 2002-02-18
KR100879232B1 (ko) 2009-01-20
EP1305334A1 (en) 2003-05-02
US7638607B2 (en) 2009-12-29
PT1305334E (pt) 2008-12-30
KR20030074589A (ko) 2003-09-19
JP4873825B2 (ja) 2012-02-08
CA2418144A1 (en) 2002-02-14
CA2418144C (en) 2013-06-18
US20070191592A1 (en) 2007-08-16
CN1484650A (zh) 2004-03-24
JP2004505640A (ja) 2004-02-26
US20050191650A1 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
CY1110424T1 (el) Πρωτεϊνες ουροκορτινης και χρησεις αυτων
Lee et al. Antibacterial peptides from pig intestine: isolation of a mammalian cecropin.
Wistow Domain structure and evolution in α-crystallins and small heat-shock proteins
ATE358724T1 (de) Expression regulierende sequenzen vom schimmelpilz chrysosporium
DE60335726D1 (de) Chromoprotein und fluoroproteine
DK1908772T3 (da) Polypeptider og polynucleinsyrer af phorphorymonas gingivalis
Lee et al. A sapecin homologue of Holotrichia diomphalia: purification, sequencing and determination of disulfide pairs
FI930626A0 (fi) Proteinstruktur hos vaexttoxingelonin
DK0594771T3 (da) Cycloheximidresistens i nukleotidsekvenser og -proteiner
EP1117682A4 (en) Novel peptides
DE69935599D1 (de) Modifizierte hcv peptid-impfstoffe
Reid Amino acid sequence of the N-terminal forty-two amino acid residues of the C chain of subcomponent C1q of the first component of human complement
Leszyk et al. Amino acid sequence of a 15 kilodalton actin-binding fragment of turkey gizzard caldesmon: Similarity with dystrophin, tropomysin and the tropomyosin-binding region of troponin T
ES2164297T3 (es) Preparacion de (poli)peptidos purificados.
ATE449107T1 (de) Aus fisch gewonnene peptide und nukleinsäuren der cathelicidin familie und deren verwendung
ATE281519T1 (de) Klonierung und rekombinante herstellung des crf- rezeptors (crf=corticotropin ausloese faktor)
ATE389720T1 (de) Nierenspezifischer urattransporter und dessen gen
Tanaka et al. Heterogeneity of the principal sigma factor in Escherichia coli: The rpoS gene product, sigma super (38), is a second principal sigma factor of RNA polymerase in stationary-phase Escherichia coli.
WO2007058267A8 (ja) 新規タンパク質及びそれをコードする遺伝子
Smith et al. Disulfide bonds in a recombinant protein modeled after a core repeat in an aquatic insect's silk protein
Strasser et al. Variable and constant regions in the C‐terminus of vinculin and metavinculin: Cloning and expression of fragments in E. coli
Brandt et al. Variants of wheat histone H1 with N-and C-terminal extensions
Tchouatcha-Tchouassom et al. Isolation and characterisation of five histone H1 subtypes from adult rat liver
WO2004013167A3 (en) Purified polypeptides from enterococcus faecalis
DE69731312D1 (de) Peptide spezifisch für antikörper gegen peptidconcensussequenzen aus der cs4-cfa/iprpteinfamilie